1. Home
  2. KWY vs OABI Comparison

KWY vs OABI Comparison

Compare KWY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kingsway Corporation Common Stock

KWY

Kingsway Corporation Common Stock

N/A

Current Price

$9.72

Market Cap

293.1M

Sector

Finance

ML Signal

N/A

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$4.10

Market Cap

294.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KWY
OABI
Founded
N/A
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.1M
294.3M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
KWY
OABI
Price
$9.72
$4.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
45.3K
2.1M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.56
EPS
N/A
N/A
Revenue
$134,996,000.00
$18,666,000.00
Revenue This Year
N/A
$52.42
Revenue Next Year
N/A
$64.69
P/E Ratio
N/A
N/A
Revenue Growth
23.42
N/A
52 Week Low
$8.41
$1.32
52 Week High
$11.36
$5.43

Technical Indicators

Market Signals
Indicator
KWY
OABI
Relative Strength Index (RSI) 43.15 51.56
Support Level $8.58 $1.71
Resistance Level $9.60 $5.43
Average True Range (ATR) 0.35 0.33
MACD -0.08 -0.13
Stochastic Oscillator 1.51 4.28

Price Performance

Historical Comparison
KWY
OABI

About KWY Kingsway Corporation Common Stock

Kingsway Corp is a U.S.-based company employing the Search Fund model to acquire and build great businesses. The company owns and operates a collection of B2B and B2C services companies that are asset-light, growing, profitable, and that have recurring revenues. It seeks to compound long-term shareholder value on a per share basis via its decentralized management model, its talented team of operators, and its tax-advantaged corporate structure.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: